Aa
REP 2139-Ca - Replicor to Present at the 2015 Lancet Viral Hepatitis Conference
http://www.businesswire.com/news/home/20150410005044/en/Replicor-Present-2015-Lancet-Viral-Hepatitis-Conference#.VSehXhebNEQ
April 10, 2015 06:00 AM Eastern Daylight Time
NEW YORK--(BUSINESS WIRE)--Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B (HBV) and hepatitis D (HDV) infection, today announced that it will present updated clinical data at the Lancet Viral Hepatitis Conference in Shanghai, China from April 10-12, 2015. The data are from studies involving patients with chronic HBV infection who were treated with REP 2139-Ca in combination with immunotherapy and /or entecavir (ETV).
REP 2139-Ca used alone or in combination with Pegasys®, ZADAXIN® or Pegasys® and ETV was safe and well-tolerated and resulted in an antiviral response that was profound and includes: the elimination (up to 7 log reduction to LLOQ) of HBsAg in the blood seroconversion for both HBsAg and HBeAg and, the elimination (up to 6 log reduction to LLOQ) of serum HBV DNA. These clinical trials indicated that REP 2139-Ca appears to significantly increase the 12-month SVR rate achieved compared to existing therapies.
Replicor’s poster presentation will be available on the company’s website at the end of the conference at www.replicor.com/science/conference-presentations. For more information on the 2015 Lancet Viral Hepatitis Meeting: www.asianoncologysummit.com/vhep-summit.asp
-----
Any comments appreciated guys
April 10, 2015 06:00 AM Eastern Daylight Time
NEW YORK--(BUSINESS WIRE)--Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B (HBV) and hepatitis D (HDV) infection, today announced that it will present updated clinical data at the Lancet Viral Hepatitis Conference in Shanghai, China from April 10-12, 2015. The data are from studies involving patients with chronic HBV infection who were treated with REP 2139-Ca in combination with immunotherapy and /or entecavir (ETV).
REP 2139-Ca used alone or in combination with Pegasys®, ZADAXIN® or Pegasys® and ETV was safe and well-tolerated and resulted in an antiviral response that was profound and includes: the elimination (up to 7 log reduction to LLOQ) of HBsAg in the blood seroconversion for both HBsAg and HBeAg and, the elimination (up to 6 log reduction to LLOQ) of serum HBV DNA. These clinical trials indicated that REP 2139-Ca appears to significantly increase the 12-month SVR rate achieved compared to existing therapies.
Replicor’s poster presentation will be available on the company’s website at the end of the conference at www.replicor.com/science/conference-presentations. For more information on the 2015 Lancet Viral Hepatitis Meeting: www.asianoncologysummit.com/vhep-summit.asp
-----
Any comments appreciated guys
no the best results were on rep9ac+pegintf 48weeks plus etv, longterm svr>12months on 4 (5 patients treated)
i think the best way before new treatments are available is:
rep9ac+tdf or etv+pegintf possibly with a low baseline hbsag by many years of nucs
the point is will replicor sell this treatment somewhere?what price?do they have a patent and will it expire?
i think the best way before new treatments are available is:
rep9ac+tdf or etv+pegintf possibly with a low baseline hbsag by many years of nucs
the point is will replicor sell this treatment somewhere?what price?do they have a patent and will it expire?
The recent one will be the preliminary clinical data from their HBV/HDV clinical trial. There will be an oral presentation at EASL - this is the one to watch, as it is an on-going trial, hopefully it will attract the attention it deserves.
All the old results are good, just that they do not seem to generate big investments in the company.
All the old results are good, just that they do not seem to generate big investments in the company.
seems that REP 2139-Ca + partial immunotherapy has the best results. What means partial immunotherepy there ? Is that approach also available for HBeAg- ?
Have an Answer?
You are reading content posted in the Hepatitis B Community
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
